Seeff Laura C, DeGroff Amy, Tangka Florence, Wanliss Ena, Major Anne, Nadel Marion, Ryerson A Blythe, Royalty Janet, Gelb Cynthia, Reed Eddie
Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, 4770 Buford Hwy, Mailstop K-52, Atlanta, GA 30341-3717, USA.
Prev Chronic Dis. 2008 Apr;5(2):A64. Epub 2008 Mar 15.
Colorectal cancer is the second leading cause of cancer-related mortality among U.S. adults. In 2004, treatment costs for colorectal cancer were $8.4 billion. There is substantial evidence that colorectal cancer incidence and mortality are reduced with regular screening. The natural history of this disease is also well described: most colorectal cancers develop slowly from preexisting polyps. This slow development provides an opportunity to intervene with screening tests, which can either prevent colorectal cancer through the removal of polyps or detect it at an early stage. However, much less is known about how best to implement an effective colorectal cancer screening program. Screening rates are low, and uninsured persons, low-income persons, and persons who have not visited a physician within a year are least likely to be screened. Although the Centers for Disease Control and Prevention (CDC) has 15 years of experience supporting the National Breast and Cervical Cancer Early Detection Program for the underserved population, a similar national program for colorectal cancer is not in place. To explore the feasibility of implementing a national program for the underserved U.S. population and to learn which settings and which program models are most viable and cost-effective, CDC began a 3-year colorectal cancer screening demonstration program in 2005. This article describes briefly this demonstration program and the process CDC used to design it and to select program sites. The multiple-methods evaluation now under way to assess the program's feasibility and describe key outcomes is also detailed. Evaluation results will be used to inform future activities related to organized screening for colorectal cancer.
结直肠癌是美国成年人癌症相关死亡的第二大主要原因。2004年,结直肠癌的治疗费用为84亿美元。有大量证据表明,定期筛查可降低结直肠癌的发病率和死亡率。这种疾病的自然史也有详尽描述:大多数结直肠癌是由先前存在的息肉缓慢发展而来。这种缓慢发展为通过筛查测试进行干预提供了机会,筛查测试既可以通过切除息肉预防结直肠癌,也可以在早期检测到它。然而,对于如何最好地实施有效的结直肠癌筛查计划,人们了解得要少得多。筛查率很低,未参保者、低收入者以及一年内未看过医生的人最不可能接受筛查。尽管疾病控制与预防中心(CDC)在为服务不足人群支持国家乳腺癌和宫颈癌早期检测计划方面有15年的经验,但尚未有类似的全国性结直肠癌计划。为了探索为美国服务不足人群实施全国性计划的可行性,并了解哪些环境和哪些计划模式最可行且具有成本效益,CDC于2005年启动了一项为期3年的结直肠癌筛查示范项目。本文简要介绍了该示范项目以及CDC用于设计它和选择项目地点的过程。还详细介绍了目前正在进行的旨在评估该项目可行性并描述关键结果的多方法评估。评估结果将用于为未来与有组织的结直肠癌筛查相关的活动提供信息。